Nantes

• First-in-human study of ICT01 in patients with advanced-stage, relapsed/refractory cancer Ended recruitment
  2024-515560-30-00 7 2020-03-05 Advanced-stage, relapsed/refractory cancer
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Ended recruitment
  2024-511653-22-00 5 2020-02-12 Cutaneous Squamous Cell Carcinoma (CSCC)
• A phase I dose-escalation study testing the feasibility and the tolerance of infusion of a third party suicide gene-transduced anti-HLA-DPB1 … Ended recruitment
  2024-515504-39-00 7 2020-02-09 Patients with hematological malignancies (Cf. inclusion criteria) HLA-
• An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma Ended recruitment
  2023-506587-13-00 4 2020-01-30 Multiple Myeloma
• MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial Ended recruitment
  2024-512269-14-00 5 2020-01-27 GIant cell Arteritis
• Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab. Ended recruitment
  2023-510248-19-00 5 2020-01-21 Eosinophilic Granulomatosis with Polyangiitis (EGPA)
• Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell … Ended recruitment
  2023-509908-15-00 10 2020-01-20 Mantle Cell Lymphoma
• ELEVATE UC OLE: An Open-Label Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2024-515156-21-00 5 2020-01-09 Ulcerative Colitis
• A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previo … Ended recruitment
  2024-511747-25-00 4 2019-12-23 B-cell non-Hodgkin lymphoma (NHL)
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in combination with best supportive … Ended recruitment
  2023-507443-10-00 5 2019-11-04 Patients with somatostatin receptor positive, well-differentiated G2 a
• Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch … Ended recruitment
  2022-502354-14-00 5 2019-10-28 Completely resected Stage IIb/c melanoma
• A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su … Ended recruitment
  2024-514088-25-00 5 2019-10-07 Multiple Myeloma
• Respiratory effect of the LISA (Less Invasive surfactant administration) method with sedation by propofol versus absence of sedation: Double … Ended recruitment
  2024-518836-36-00 5 2019-10-07 Respiratory Distress Syndrome of preterm babies born < 32 weeks of ges
• A study of androgen deprivation therapy (ADT) plus apalutamide in patients with prostate cancer Ended recruitment
  2023-506153-38-00 5 2019-07-11 High-risk localized or locally advanced prostate cancer
• Randomized double blind double dummy control trial comparing the safety and efficacy of rituximab versus oral cyclophosphamide in severe for … Ended recruitment
  2024-514885-38-00 5 2019-07-11 severe forms of mucous membrane pemphigoid
• OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN A … Ended recruitment
  2024-516048-24-00 4 2019-06-19 CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST
• Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto … Ended recruitment
  2023-504932-16-00 5 2019-06-04 Muscle Invasive Bladder Cancer
• Study of the efficacy of treatment with AG-120 in patients with Myelodysplastic Syndrome and mutation IDH1 Ended recruitment
  2024-515352-20-00 4 2019-03-20 myelodysplastic syndrome with IDH1 mutated
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia
• study of the efficacy of treatment with AG-221 in patients with myelodysplastic syndrome and mutation IDH2 Ended recruitment
  2024-513858-29-01 4 2019-02-06 myelodysplastic syndrome with IDH2 mutated
• Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma … Ended recruitment
  2022-502937-24-00 5 2019-01-02 Atopic Dermatitis
• A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended recruitment
  2023-506125-10-00 5 2018-12-24 Multiple Myeloma
• A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or inter … Ended recruitment
  2022-501485-22-00 5 2018-12-18 Myelodysplastic syndrome (MDS)

Showing 601–624 of 800 trials